Synaptix Biotherapeutics

Synaptix Biotherapeutics is a biotechnology company focused on developing antisense oligonucleotide (ASO) therapies for rare neurodegenerative diseases, specifically GM2 gangliosidosis. The company's lead program, SYN-001, targets Tay-Sachs disease by addressing the underlying genetic deficiency of the HEXA gene. Synaptix operates through a close collaboration with the National Institutes of Health (NIH) and the National Center for Advancing Translational Sciences (NCATS) to accelerate the development of its pipeline. By utilizing ASO technology, the company aims to provide the first effective treatments for patients suffering from these devastating and often fatal lysosomal storage disorders.